Phenacemide

Phenacemide
Clinical data
Trade names	Phenurone
AHFS/Drugs.com	Micromedex Detailed Consumer Information
ATC code	N03AX07 (WHO) ;
Pharmacokinetic data
Elimination half-life	22–25 hours
Identifiers
	IUPAC name N-Carbamoyl-2-phenyl-acetamide;
CAS Number	63-98-9 ;
PubChem CID	4753;
IUPHAR/BPS	7265;
DrugBank	DB01121 ;
ChemSpider	4589 ;
UNII	PAI7J52V09;
KEGG	D00504 ;
ChEMBL	ChEMBL918 ;
CompTox Dashboard (EPA)	DTXSID6023442 ;
ECHA InfoCard	100.000.519
Chemical and physical data
Formula	C9H10N2O2
Molar mass	178.191 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(NC(=O)N)Cc1ccccc1;
	InChI InChI=1S/C9H10N2O2/c10-9(13)11-8(12)6-7-4-2-1-3-5-7/h1-5H,6H2,(H3,10,11,12,13) ; Key:XPFRXWCVYUEORT-UHFFFAOYSA-N ;
	(verify)

Phenacemide (INN, BAN) (brand name Phenurone), also known as phenylacetylurea, is an anticonvulsant of the ureide (acetylurea) class.^[1] It is a congener and ring-opened analogue of phenytoin (a hydantoin),^[2]^[3] and is structurally related to the barbiturates and to other hydantoins.^[4] Phenacemide was introduced in 1949 for the treatment of epilepsy, but was eventually withdrawn due to toxicity.^[2]^[3]